Jyong Biotech Ltd. Ordinary Shares (MENS) vs Veraxa Biotech Holding AG (VRXA)

A side-by-side comparison of Jyong Biotech Ltd. Ordinary Shares and Veraxa Biotech Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

MENS

Jyong Biotech Ltd. Ordinary Shares

$154M

$2.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

VRXA

Veraxa Biotech Holding AG

$153M

$1.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — MENS vs VRXA

growth of $100 · dividends reinvested · last 1y

MENS -1.9% (-1.9%/yr)VRXA -90.8% (-90.8%/yr)MENS compounded faster over this window

Log scale — wide-divergence pair

MENS VRXA

Metrics side by side

Total return (annualized)

Metric	MENS	VRXA
Total return (1Y)	-95.66%	N/A

MENS is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full MENS analysis Full VRXA analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.